Susquehanna International Group, LLP Alzamend Neuro, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 16, 2023	SELL	$0.37 - $0.71 $24,457 - $46,931	-66,100 Reduced 33.07%	133,800 $56,000
Q4 2022 Feb 14, 2023	SELL	$0.53 - $222.0 $65,879 - $27.6 Million	-124,300 Reduced 38.34%	199,900 $111,000
Q3 2022 Nov 14, 2022	BUY	$0.88 - $178.5 $238,216 - $48.3 Million	270,700 Added 505.98%	324,200 $386,000
Q2 2022 Aug 15, 2022	BUY	$0.82 - $1.2 $28,536 - $41,760	34,800 Added 186.1%	53,500 $46,000
Q1 2022 May 16, 2022	SELL	$0.91 - $2.23 $9,100 - $22,300	-10,000 Reduced 34.84%	18,700 $23,000
Q4 2021 Feb 14, 2022	BUY	$1.9 - $3.08 $54,530 - $88,396	28,700 New	28,700 $55,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $122M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.